We use cookies to help us improve your experience and to provide services like web chat. We also use cookies to measure the effectiveness of public health campaigns and understand how people use the website.

To find out more about cookies and how we use them, please see our privacy policy.

Lidocaine 5% plaster

Lidocaine 5% medicated plaster (Versatis®) is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection known as post-herpetic neuralgia (PHN) in adults. 

The HSE Medicines Management Programme (MMP) has reviewed the evidence available to support the use of lidocaine 5% medicated plaster (Versatis®).

Download the MMP Prescribing and Cost Guidance report on lidocaine 5% medicated plaster.

Following this review and based on best practice recommendations, the Primary Care Reimbursement Service (PCRS) are introducing changes to the reimbursement of lidocaine 5% medicated plaster from 1 September 2017. This process will support appropriate use of this medication while ensuring those with an indication of PHN continue to have access to this treatment.

Summary of the Prescribing and Cost Guidance report and information on changes to reimbursement.

Prescribing “Tips and Tools” are available to guide appropriate use of lidocaine 5% medicated plaster and offer topical treatment alternatives for both PHN and other types of pain.

Download Prescribing “Tips and Tools” for lidocaine 5% medicated plaster.

Questions and Answers for healthcare professionals are available to explain the reimbursement process for new and existing patients on lidocaine 5% medicated plaster.
Click on the link below to assess Questions and Answers for healthcare professionals.

Download Questions and Answers for healthcare professionals.

Information for patients is also available to explain the changes in relation to lidocaine 5% medicated plaster.

Information for patients Lidocaine 5%Information for patients Lidocaine 5%.pdf (size 225.8 KB)

Letter from Medicines Management Programme to Prescribers

Download letter from MMP about lidocaine 5% medicated plaster

Clinical Strategy and Programmes Division